United Therapeutics (UTHR) investor relations material

Product pipeline and innovation

• Fourteen major products are being launched, targeting pulmonary fibrosis, pulmonary hypertension, and related diseases, with several NDAs filed and key PDUFA dates in 2025 and 2026.

• Ralinepag, a once-daily pill for pulmonary hypertension, is expected to become the leading therapy in its field, with strong IP protection into the 2040s.

• The company is developing combination therapies and new delivery methods, including soft mist inhalers and DPI formulations, to address large patient populations.

• A robust pipeline includes products for COPD-PH and a rescue inhaler for PH, aiming to address over 1 million patients in the coming years.

• Ralpi, a next-generation molecule with superior efficacy and patent protection, is positioned for launch around 2030, targeting $100 billion in annual revenue.

Financial strategy and capital allocation

• A $2 billion share repurchase program is underway, reflecting confidence in future growth and current stock value.

• Capital deployment is focused on both product development and strategic investments, including scaling organ manufacturing facilities as clinical trials progress.

• Facility investments have shifted to a more scalable, cost-effective model, supporting future commercialization needs.

Disruptive culture and organizational approach

• The organization identifies as a disruptor, not a traditional leader, focusing on challenging established markets in pulmonary and fibrotic diseases.

• A high-revenue-per-employee model and a Darwinian business culture drive efficiency and innovation.

• The internal term "Unitherians" reflects a shared commitment to ambitious goals and patient-centric innovation.

• The company’s mantra is to question authority and pursue neglected opportunities in healthcare.